A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Rheumatoid Arthritis
Latest Information Update: 22 Dec 2022
At a glance
- Drugs Infliximab (Primary) ; Folic acid; Infliximab; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Celltrion
- 19 Dec 2022 Results of a post-hoc analysis assessing the efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis, published in the Rheumatology
- 04 Jun 2022 Results of a post-hoc analysis assessing difference in efficacy outcomes between SC and IV IFX at weeks 30 and 54 presented at the 23rd Annual Congress of the European League Against Rheumatism
- 31 May 2022 According to a Celltrion Media Release, results of a post-hoc analysis were presented at the Annual European Congress of Rheumatology (EULAR 2022).